The ensuing analyses yielded findings that suggest ITM2A as a promising therapeutic target for triple-negative breast cancer, with potential implications in both immune-related and prognostic-related contexts, as well as in the context of copper-death-related processes. Here, ITM2A is linked to triple-negative breast carcinoma.